



INSTITUT
JULES BORDET
INSTITUUT

Clinical Trial Title : « Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α -2b »

EudraCT Number : «2012-005545-20»

Protocol Number :« IJBNMDOCASTOR»

Study name : «CaStOR»

NO or PARTIAL RESULTS FOR THIS TRIAL

(I) Accrual

- The trial is terminated before any subject was recruited.
- The trial is terminated whereas _____ subjects/ _____ were recruited.

(II) Reasons

- The positive opinion by the Ethics Committee in charge of the trial is not granted or is irrevocably revoked.
- The authorisation by the Competent Authority of the Member State concerned in charge of the trial is not granted or is irrevocably revoked.
- The sponsor became or was declared insolvent or a petition in bankruptcy has been filed against it or it is dissolved.
- Early end of the scientific collaboration with one or more partners.
- Early termination due to safety.
- Discontinuation or change of the strategic direction of the development of the medicinal product(s) that the sponsor wanted to study.
- Trial logistics or limited trial population, as defined by the inclusion/exclusion criteria, leading to a poor recruitment.
- Publication of other clinical trials which changed the therapeutic landscape and rendered our trial design obsolete.
- Publication of other clinical trials already demonstrating the clinical interest of our trial and rendered our trial obsolete.

Rue Héger-Bordetstraat 1, B-1000 Bruxelles/Brussel
T + 32 (0)2 541 31 11, F + 32 (0)2 541 35 06, BELFIUS 091-0097278-16, www.bordet.be

Institut Jules Bordet, Association Hospitalière de Bruxelles régie par la loi du 8 juillet 1976
Jules Bordet Instituut, Ziekenhuisvereniging van Brussel onderworpen aan de wet van 8 juli 1976